Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: A systematic review and meta-analysis

Thorax

Volumn 68, Issue 5, 2013, Pages 442-450

  Zhang, Jing ^a   Zhang, Yue Li ^b   Ma, Kai Xiang ^c   Qu, Jie Ming ^b  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

^c Fuyuan People's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; CERTOPARIN; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ADVANCED CANCER; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 84876298136     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202592     Document Type: Article

References (34)

1. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012;9:e1001275.
2. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22. (Pubitemid 40216041)
3. Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601-8. (Pubitemid 351404927)
4. Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010;104:1049-54.
5. Huang H, Korn JR, Mallick R, et al. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study. J Thromb Thrombolysis 2012;34:446-56.
6. Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007;13:362-7. (Pubitemid 47472294)
7. Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol) 2007;19:494-8. (Pubitemid 47181178)
8. Seitz R, Heidtmann HH, Wolf M, et al. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol 1997;8:781-4. (Pubitemid 27397902)
9. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50. (Pubitemid 32104130)
10. Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol 2010;3:3.
11. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. 'Petites Cellules' Group. Cancer 1994;74:38-45. (Pubitemid 24187607)
12. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-71. (Pubitemid 40186120)
13. Maurer LH, Herndon JE II, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997;15:3378-87. (Pubitemid 27485858)
14. Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002. (Pubitemid 19196521)
15. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-9.
16. Haas SK, Freund M, Heigener D, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012;18:159-65.
17. van Doormaal FF, Di Nisio M, Otten HM, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29:2071-6.
18. Jadad ARMR, Carroll D, Jenkinson C, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
19. Higgins JPTS. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-8.
20. Stanford CF. Anticoagulants in the treatment of small cell carcinoma of the bronchus. Thorax 1979;34:113-16. (Pubitemid 9138543)
21. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984;53:2046-52. (Pubitemid 14101772)
22. Akl EA, Gunukula S, Barba M, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011;(1):CD006652.
23. Akl EA, Vasireddi SR, Gunukula S, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011;(6):CD006466.
24. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-8. (Pubitemid 41095187)
25. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5. (Pubitemid 46218704)
26. Verso M, Gussoni G, Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 2010;8:1649-51.
27. Kakkar AK, Macbeth F. Antithrombotic therapy and survival in patients with malignant disease. Br J Cancer 2010;102(Suppl 1):S24-9.
28. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002;28:45-52. (Pubitemid 34194872)
29. Mousa SA, Mohamed S. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncol Rep 2004;12:683-8.
30. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999;91:22-36. (Pubitemid 29042440)
31. Le Maitre A, Ding K, Shepherd FA, et al. Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. J Thorac Oncol 2009;4:586-94.
32. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53. (Pubitemid 36818784)
33. Akl EA, Barba M, Rohilla S, et al. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008;27:21.
34. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7S-47S.